XenoGesis Limited

Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

AcZon is an Italian Company specializing in biotechnology that develops, produces and commercializes Silica Nanoparticles (Nanoprobes) - for diagnostic, clinical and research fields- as well as a range of conventional reagents optimized for various applications as, for example, fluorescent antibodies. People’s Health is the main focus and ultimate goal of our business; our “mission” is basically “To promote and providing Reagents for Diagnostics and Research, with very high brilliance and clarity of image, stability and sensitivity, by offering products and services that speed-up the diagnostic response time, provide a better service to the patient”. AcZon focuses with growing interest on the amazing potentials offered by combining chemistry, biotechnology and nanotechnology. Indeed, on this basis, AcZon has developed and optimized a line of new products (reagents for in vitro diagnostics and research) characterized by outstanding performances. Thanks to its team of researchers (chemists and biologists), all with considerable experience in the synthesis and functionalization of polymers and in the fields of immunology, proteins and bio-conjugations, AcZon has developed, and is now producing, a line of NanoProbes (proprietary technology), based on Silica NanoParticles (NPs), which are not exclusively suitable for diagnostic and clinical applications, but also for chemistry, pharmacy, agriculture and the environment

ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release'​ technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release'​ platform drives value through better products delivered with greater efficiency.

In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.

For more information on our services and Lock Release please visit

www.adcbio.com

Admescope is a contract research organisation (CRO) providing the pharmaceutical, biotechnology and veterinary industry with premium quality tailor-made services to drug discovery in the area of ADME-Tox.

The service offering is widely spread, from highly tailored and optimised studies to high-throughput screening. Admescope’s unique expertise lies in in vitro & in vivo drug metabolism; including metabolite profiling & identification, drug-drug interactions and quantitative bioanalysis. The right level of research can always be found for the customer whether in the discovery or lead optimisation phase.

All of the services include comprehensive study consulting which enables tailoring the study according to customers’ specific needs. The state-of-art quality data is ensured by optimising the conditions according to the compounds instead of using generic protocols. All of the data can be interpreted for the customer and helped to understand the real meaning of the numerical values and observations.

Service Offering

• in vitro Metabolism
• in vivo DMPK
• Drug Interactions
• Quantitative Bioanalysis
• Permeability & Transporters
• Physicochemistry & Binding
• in vitro Toxicology
• Biologics

Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.

Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.

We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.

Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.

Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.

The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.